UCB shares dip, analyst and company point to prescription data slowdown for BimzelX

UCB SA

31/10/2025 15:57

Updates

** Shares in Belgian drugmaker UCB UCB.BR slide 7.6% to their lowest price in a month

** Two analysts point to a slowdown in early prescription data for its flagship skin disease product, BimzelX

** One analyst, who preferred to be unnamed, notes that disruptions at prescription data gatherer IQVIA add to uncertainty, as UCB has said data for October will be restated but has not released when that would be

** The drop follows a downgrade from Jefferies earlier this week saying the "BimzelX bonanza" showed signs of steadying pace

** UCB in an email confirmed disruptions between October 10 and October 24, anticipating about 10% of weekly reported prescriptions will be added to the data over the next two to three weeks to account for the backlogged data

 (Reporting by Jakob Van Calster and Jerome Terroy)

 ((jakob.vancalster@thomsonreuters.com))